NASDAQ:CALA - Calithera Biosciences Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started $4.70 -0.05 (-1.05 %) (As of 07/17/2018 08:00 AM ET)Previous Close$4.75Today's Range$4.55 - $4.7552-Week Range$4.30 - $18.95Volume171,900 shsAverage Volume438,468 shsMarket Capitalization$170.26 millionP/E RatioN/ADividend YieldN/ABeta2.53 Company ProfileFinancialsAnalyst RatingsEarnings HistoryInsider TradesHeadlinesOptions ChainSEC FilingsSocial MediaChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Calithera Biosciences, Inc., a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. Its lead product candidate is CB-839, an inhibitor of glutaminase, which is in Phase II clinical trial to treat solid tumors. The company also offers INCB001158, an oral inhibitor of arginase that is in Phase I/II clinical trial for the treatment of hematology and oncology. It has a license agreement with Mars, Inc. to develop and commercialize Symbioscience's portfolio of arginase inhibitors for use in human healthcare; and license and research agreement with High Point Pharmaceuticals, LLC and TransTech Pharma LLC to develop and commercialize hexokinase II inhibitors. The company also has clinical trial collaboration with Bristol-Myers Squibb Company to evaluate nivolumab in combination with CB-839 in cell renal cell carcinoma. In addition, it has a collaboration and license agreement with Incyte Corporation for the research, development, and commercialization of INCB001158, a small molecule arginase inhibitor for the treatment of hematology and oncology. Calithera Biosciences, Inc. was founded in 2010 and is headquartered in South San Francisco, California. Receive CALA News and Ratings via Email Sign-up to receive the latest news and ratings for CALA and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical SymbolNASDAQ:CALA CUSIPN/A Webwww.calithera.com Phone650-870-1000 Debt Debt-to-Equity RatioN/A Current Ratio5.27 Quick Ratio5.27 Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$25.95 million Price / Sales6.49 Cash FlowN/A Price / CashN/A Book Value$4.24 per share Price / Book1.11 Profitability EPS (Most Recent Fiscal Year)($0.84) Net Income$-27,820,000.00 Net Margins-131.51% Return on Equity-22.92% Return on Assets-17.93% Miscellaneous Employees73 Outstanding Shares35,850,000Market Cap$170.26 Calithera Biosciences (NASDAQ:CALA) Frequently Asked Questions What is Calithera Biosciences' stock symbol? Calithera Biosciences trades on the NASDAQ under the ticker symbol "CALA." How were Calithera Biosciences' earnings last quarter? Calithera Biosciences Inc (NASDAQ:CALA) announced its quarterly earnings results on Thursday, May, 10th. The biotechnology company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.32) by $0.05. The biotechnology company earned $5.19 million during the quarter, compared to analysts' expectations of $7.28 million. Calithera Biosciences had a negative return on equity of 22.92% and a negative net margin of 131.51%. View Calithera Biosciences' Earnings History. What price target have analysts set for CALA? 3 Wall Street analysts have issued 12 month price targets for Calithera Biosciences' stock. Their predictions range from $14.00 to $14.00. On average, they expect Calithera Biosciences' stock price to reach $14.00 in the next twelve months. This suggests a possible upside of 197.9% from the stock's current price. View Analyst Ratings for Calithera Biosciences. What is the consensus analysts' recommendation for Calithera Biosciences? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Calithera Biosciences in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." Are investors shorting Calithera Biosciences? Calithera Biosciences saw a drop in short interest during the month of June. As of June 29th, there was short interest totalling 1,468,140 shares, a drop of 32.1% from the June 15th total of 2,163,551 shares. Based on an average daily trading volume, of 622,955 shares, the days-to-cover ratio is currently 2.4 days. Approximately 5.1% of the company's stock are sold short. View Calithera Biosciences' Current Options Chain. Who are some of Calithera Biosciences' key competitors? Some companies that are related to Calithera Biosciences include ChemoCentryx (CCXI), Vectura Group (VEGPF), Kura Oncology (KURA), Dicerna Pharmaceuticals (DRNA), Dova Pharmaceuticals (DOVA), Urogen Pharma (URGN), Collegium Pharmaceutical (COLL), Viking Therapeutics (VKTX), Arbutus Biopharma (ABUS), Odonate Therapeutics (ODT), Aclaris Therapeutics (ACRS), Geron (GERN), Evolus (EOLS), Progenics Pharmaceuticals (PGNX) and Innovate Biopharmaceuticals (INNT). Who are Calithera Biosciences' key executives? Calithera Biosciences' management team includes the folowing people: Dr. Susan M. Molineaux, Co-Founder, CEO, Pres & Director (Age 64)Ms. Sumita Ray, Sr. VP, Gen. Counsel & Chief Compliance Officer (Age 44)Dr. Keith Orford, Sr. VP of Clinical Devel. (Age 46)Ms. Stephanie Wong, Sr. VP of Fin. & Sec. (Age 44)Ms. Jennifer McNealey, VP of Investor Relations & Strategy Has Calithera Biosciences been receiving favorable news coverage? Headlines about CALA stock have been trending somewhat positive on Tuesday, Accern reports. The research group scores the sentiment of press coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Calithera Biosciences earned a media sentiment score of 0.20 on Accern's scale. They also gave news headlines about the biotechnology company an impact score of 46.60 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the next several days. How do I buy shares of Calithera Biosciences? Shares of CALA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Calithera Biosciences' stock price today? One share of CALA stock can currently be purchased for approximately $4.70. How big of a company is Calithera Biosciences? Calithera Biosciences has a market capitalization of $170.26 million and generates $25.95 million in revenue each year. The biotechnology company earns $-27,820,000.00 in net income (profit) each year or ($0.84) on an earnings per share basis. Calithera Biosciences employs 73 workers across the globe. How can I contact Calithera Biosciences? Calithera Biosciences' mailing address is 343 OYSTER POINT BLVD. SUITE 200, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at 650-870-1000 or via email at [email protected] MarketBeat Community Rating for Calithera Biosciences (NASDAQ CALA)Community Ranking: 2.9 out of 5 ( )Outperform Votes: 192 (Vote Outperform)Underperform Votes: 138 (Vote Underperform)Total Votes: 330MarketBeat's community ratings are surveys of what our community members think about Calithera Biosciences and other stocks. Vote "Outperform" if you believe CALA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CALA will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/17/2018 by MarketBeat.com StaffFeatured Article: Are analyst ratings accurate?